Study Enrollment

Your details will not be published or shared.

Clinical Trial

POLAR 209035: A Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 infected Adults who are Virologically Suppressed and Participated in Study LAI116482 (Pro00025197)

This study is designed for patients currently being followed in another GSK study, called LATTE, to go into when LATTE finishes. Those patients will have the choice to receive the same oral drug they were getting in LATTE, or switch to the new injection medication that is being studied, to treat their HIV.

Eligibility Criteria

  • INCLUSION: 1. Adult age 18 years or older who is currently receiving the oral study drugs via the LATTE study. 2. HIV count EXCLUSION: 1. HIV counts and other lab values outside of ranges required by this new study. 2. Any medical conditions not allowed by the study.

Contact Information

    Marti Farrough

    (706) 723-0106